Alex joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial and operational experience in the biotechnology industry to her role.
Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she was responsible for strategic planning, finance and accounting. During her time at SQZ Biotechnologies, she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Before joining SQZ, Alex served as Corporate Controller at Agios Pharmaceuticals, where she built the finance and accounting teams and contributed to the company’s strategic financing efforts, raising more than $700 million in equity financing, including playing a key role in the 2013 initial public offering. Alex was responsible for all financial functions of the company including strategic planning, treasury, tax, finance and accounting. Earlier in her career, Alex held positions at both Molecular Insight Pharmaceuticals, a publicly-traded oncology company, acquired in 2013 and Coley Pharmaceuticals, a publicly-traded company developing immunotherapies for cancer and other disease areas, acquired by Pfizer in 2007.
Alex earned her B.B.A in finance from the University of Massachusetts, Amherst and her M.B.A from Boston College. Alex is also a certified public accountant in Massachusetts.
How do I contact Alexandra Balcom?
Has Alexandra Balcom been buying or selling shares of Nuvalent?
Alexandra Balcom has not been actively trading shares of Nuvalent during the last ninety days. Most recently, Alexandra Balcom sold 30,000 shares of the business's stock in a transaction on Monday, December 18th. The shares were sold at an average price of $75.82, for a transaction totalling $2,274,600.00. Learn More on Alexandra Balcom's trading history.
Who are Nuvalent's active insiders?
Are insiders buying or selling shares of Nuvalent?
During the last year, insiders at the sold shares 35 times. They sold a total of 1,466,651 shares worth more than $103,203,548.94. The most recent insider tranaction occured on April, 22nd when Director Matthew Shair sold 37,500 shares worth more than $2,386,875.00. Insiders at Nuvalent own 14.8% of the company.
Learn More about insider trades at Nuvalent. Information on this page was last updated on 4/22/2024.
